Akcea Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Akcea Therapeutics, Inc. reported Increase (Decrease) in Accounts Receivable of $3.55 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2020-08-05
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-06-30 was $3.38M.
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-03-31 was $177.00K, a 96.88% decline year-over-year.
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-12-31 was -$157.00K, a 103.96% decline year-over-year.
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-09-30 was $1.46M.
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2019 was $5.90M.
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2018 was -$816.00K, a 115.07% decline from fiscal 2017.
- Akcea Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2017 was $5.41M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2020-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $3.55M 10-Q · filed 2020-08-05 | $3.40M derived: sum of 3 quarters · filed 2020-08-05 | $4.86M derived: sum of 4 quarters · filed 2020-08-05 |
| 2020-03-31 | $177.00K 10-Q · filed 2020-05-06 | $20.00K derived: sum of 2 quarters · filed 2020-05-06 | $1.48M derived: sum of 3 quarters · filed 2020-05-06 | $404.00K derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.30M derived: sum of 2 quarters · filed 2020-03-02 | $227.00K derived: sum of 3 quarters · filed 2020-08-05 | $5.90M 10-K · filed 2020-03-02 |
| 2019-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $384.00K derived: sum of 2 quarters · filed 2020-08-05 | $6.06M 10-Q · filed 2019-11-06 | $10.02M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $4.60M 10-Q · filed 2020-08-05 | $8.56M derived: sum of 3 quarters · filed 2020-08-05 | $5.90M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $5.67M 10-Q · filed 2020-05-06 | $9.63M derived: sum of 2 quarters · filed 2020-05-06 | $6.97M derived: sum of 3 quarters · filed 2020-05-06 | $10.27M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.30M derived: sum of 2 quarters · filed 2020-03-02 | $4.60M derived: sum of 3 quarters · filed 2020-03-02 | -$816.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | -$2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $636.00K derived: sum of 2 quarters · filed 2019-11-06 | -$4.78M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$2.12M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | -$5.41M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $5.41M 10-K · filed 2020-03-02 |